References: Hair growth and hair loss
Cancer Res. 1991 Jun 15;51(12):3329-30.
Interleukin 1 protects against 1-beta-D-arabinofuranosylcytosine-induced alopecia in the newborn rat animal model.
Hussein AM.
William J. Harrington Center for Blood Diseases, University of Miami School of Medicine, Florida 33136.
Alopecia is one of the most psychologically distressing side effects of cancer chemotherapy. Previously, we made the following observations: (a) treatment of 8-day-old rats with 1-beta-D-arabinofuranosylcytosine (ara-C), doxorubicin, and cyclophosphamide (CYC) consistently produced either total body alopecia (ara-C and CYC) or alopecia confined to the head and proximal part of the neck (doxorubicin); (b) Imuvert, a biological response modifier derived from the bacterium Serratia marcescens, uniformly produced complete protection against alopecia induced by ara-C and doxorubicin but not that induced by CYC; and (c) the protective effect of Imuvert against chemotherapy-induced alopecia is mediated by a monocyte-mediated cytokine. In the experiments reported here, interleukin 1 was examined as the potential cytokine. Interleukin 1 offered excellent protection against alopecia induced by ara-C but not that produced by CYC in the newborn rat animal model.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2040008&dopt=Abstract
J Dermatol Surg Oncol. 1991 Jun;17(6):510-8.
Hairline design and placement.
Norwood OT, Taylor BJ.
University of Oklahoma Health Sciences Center, Oklahoma City.
A simple, straight forward, almost mechanical method of drawing the hairline is presented. It is amazing to see how this method, when followed closely, consistently produces a natural, aesthetically pleasing result on all sizes and shapes of heads. It is recognized by the authors that there are a lot of individual variations among hair transplant surgeons and most will be very attractive and quite natural. However, we believe that the following description will provide a good starting point in designing hairlines, and if the basic points are followed, unnatural hairlines will be avoided.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2040755&dopt=Abstract
Bone Marrow Transplant. 1991 Jan;7(1):43-7.
Busulphan/cyclophosphamide conditioning for bone marrow transplantation may lead to failure of hair regrowth.
Baker BW, Wilson CL, Davis AL, Spearing RL, Hart DN, Heaton DC, Beard ME.
Haematology Department, Christchurch Hospital, New Zealand.
Following the introduction of bulsulphan and cyclophosphamide (BUCY) conditioning in our unit in 1987, a number of patients noted incomplete scalp hair regrowth following bone marrow transplantation (BMT). Between August 1987 and May 1989, 22 patients had undergone allogeneic or autologous BMT in our unit and we recalled for detailed assessment the 14 who were alive and well at least 6 months post grafting. Six patients had experienced incomplete hair regrowth of varying severity 7-27 months following BMT. All those affected had received BUCY conditioning and the four most severely affected were allogeneic BMT recipients. No patient had received any post-BMT chemotherapy or radiation. None of the patients had evidence of graft-versus-host disease. No laboratory test abnormalities distinguished the affected from the unaffected patients. Despite the relatively small number of patients, our results suggest that BUCY has caused permanent damage to the hair follicles of the affected patients. Prolonged alopecia may markedly impair the quality of life for long-term survivors of BMT and this unexpected complication also has significant medicolegal implications.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2043877&dopt=Abstract
Natural Herbal Supplements ||
Hair Million herbal formula for hair loss and hair growth ||
Hair growth research references ||
Online Pharmacy : discount prescription medication ||